InvestSMART

Pharmaxis Ltd (ASX: PXS) - Announcements

- Current share price for PXS : $0.027

ASX company news and announcements for Pharmaxis Ltd (PXS) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Pharmaxis Ltd (PXS) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Pharmaxis Ltd (PXS), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Pharmaxis Ltd (PXS)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
- Appendix 4C - quarterly 12 Oct 2011 4:56PM $0.940 $0.027 fallen by 97.13%
- Phase II Trial in Allergic Asthma Completes Recruitment 29 Sep 2011 8:33AM $0.700 $0.027 fallen by 96.14%
- Update on EU Bronchitol Marketing Application 28 Sep 2011 9:35AM $0.705 $0.027 fallen by 96.17%
- Re-examination Documents Filed for EU Bronchitol Application 22 Aug 2011 9:01AM $1.025 $0.027 fallen by 97.37%
- Preliminary Final Report 12 Aug 2011 8:45AM $0.915 $0.027 fallen by 97.05%
- Appendix 4C - quarterly 20 Jul 2011 4:22PM $1.025 $0.027 fallen by 97.37%
- Bronchitol Resubmitted to Australian PBAC 12 Jul 2011 9:25AM $0.925 $0.027 fallen by 97.08%
- Re-examination of Bronchitol Marketing Application Requested 5 Jul 2011 9:10AM $1.005 $0.027 fallen by 97.31%
- EU Marketing Authorisation Application Review of Bronchitol 27 Jun 2011 10:29AM $0.900 $0.027 fallen by 97%
- EU CHMP Confirms Negative Trend Vote on Bronchitol 24 Jun 2011 11:20AM $0.935 $0.027 fallen by 97.11%
- Response to ASX Query Letter 31 May 2011 9:22AM $1.140 $0.027 fallen by 97.63%
- Pharmaxis Receives Negative Bronchitol Trend Vote from CHMP 25 May 2011 8:50AM $0.760 $0.027 fallen by 96.45%
- Trading Halt 23 May 2011 9:50AM $2.930 $0.027 fallen by 99.08%
- Bronchitol Deferred by Australian PBAC 21 Apr 2011 8:27AM $3.050 $0.027 fallen by 99.11%
- Appendix 4C - quarterly 13 Apr 2011 4:28PM $2.940 $0.027 fallen by 99.08%
- Australian TGA Approves Bronchitol for Cystic Fibrosis 8 Feb 2011 9:35AM $2.740 $0.027 fallen by 99.01%
- Half Yearly Report and Accounts 4 Feb 2011 8:47AM $2.600 $0.027 fallen by 98.96%
- Appendix 4C - quarterly 25 Jan 2011 4:22PM $2.860 $0.027 fallen by 99.06%
- EU Bronchitol Marketing Application Update 25 Jan 2011 4:20PM $2.860 $0.027 fallen by 99.06%
- Bronchitol EU Marketing Authorisation Update 20 Dec 2010 10:46AM $2.780 $0.027 fallen by 99.03%
- Extended Benefit with Bronchitol in Second PhaseIII CF Trial 16 Dec 2010 9:36AM $2.820 $0.027 fallen by 99.04%
- Bronchitol Recommended for Approval by Australian Advisory C 13 Dec 2010 9:20AM $2.890 $0.027 fallen by 99.07%
- Phase II Trial of ASM8 in Asthma Commences 7 Dec 2010 11:13AM $2.910 $0.027 fallen by 99.07%
- Pharmaxis Announces Positive Combined Phase 3 CF Results 22 Oct 2010 9:54AM $2.850 $0.027 fallen by 99.05%
- Appendix 4C - quarterly 13 Oct 2010 4:59PM $2.620 $0.027 fallen by 98.97%

676 - 700 of 836 results

Page 28 of 34

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.